Literature DB >> 12010404

Concentrate safety and efficacy.

C K Kasper1.   

Abstract

Safety from transmission of infections through plasma-derived clotting factor concentrates is assured by improved donor screening, serological testing of individual donations and direct viral testing of small plasma pools. Modern viral-inactivation techniques are highly effective. Recombinant concentrates stabilized in human albumin are being superaeded by those with other stabilizers. Recently reported discrepancies between estimates of concentrate potency from in vitro assays versus in vivo recovery, depending upon type of assay and reference standard used, are not fully resolved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010404     DOI: 10.1046/j.1365-2516.2002.00601.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

1.  Comparison among plasma-derived clotting factor VIII by using monodimensional gel electrophoresis and mass spectrometry.

Authors:  Anna Maria Timperio; Federica Gevi; Giuliano Grazzini; Stefania Vaglio; Lello Zolla
Journal:  Blood Transfus       Date:  2010-06       Impact factor: 3.443

2.  Proteomic characterization of plasma-derived clotting factor VIII-von Willebrand factor concentrates.

Authors:  James G Clifton; Feilei Huang; Spomenka Kovac; Xinli Yang; Douglas C Hixson; Djuro Josic
Journal:  Electrophoresis       Date:  2009-10       Impact factor: 3.535

3.  Use of proteomics for validation of the isolation process of clotting factor IX from human plasma.

Authors:  James Clifton; Feilei Huang; Dajana Gaso-Sokac; Kate Brilliant; Douglas Hixson; Djuro Josic
Journal:  J Proteomics       Date:  2009-10-09       Impact factor: 4.044

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.